Cox John 4
4 · Dyne Therapeutics, Inc. · Filed Sep 9, 2025
Insider Transaction Report
Form 4
Cox John
DirectorCEO & President
Transactions
- Sale
Common Stock
2025-09-05$13.41/sh−2,640$35,402→ 199,539 total
Holdings
- 18,000(indirect: By Trust)
Common Stock
- 18,000(indirect: By Trust)
Common Stock
- 18,000(indirect: By Trust)
Common Stock
- 18,000(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]The Reporting Person's sale of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to the extent of 2,640 shares, with the Reporting Person's purchase of 100,000 shares on July 14, 2025. The Reporting Person has paid to the Issuer an aggregate amount of $11,565.07, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act.
- [F3]Includes 118,057 unvested RSUs.
- [F4]These shares are held in a trust for the benefit of a child of the Reporting Person.